Retatrutide (also referred to by its development code LY3437943) is an investigational, once-weekly injection developed by Eli Lilly and Company
The development of GLP-1 medicines has transformed the therapeutic options for patients with type 2 diabetes (T2D) who are unable to achieve sufficient glucose control with existing treatments
Although ischemic optic neuropathy was rare, it is clinically important because it can involve sudden vision loss, said Chintan Dave, a core faculty member of the Center for Pharmacoepidemiology and Treatment Science at Rutgers Institute for Health, Health Care Policy and Aging Research
[DOI] [PMC free article] [PubMed] [Google Scholar] 169.Wadden T.A., Bailey T.S., Billings L.K., Davies M., Frias J.P., Koroleva A., Lingvay I., O'Neil P.M., Rubino D.M., Skovgaard D., et al
Mounjaro KwikPen 10 mg solution for injection in pre-filled pen Summary of Product Characteristics
Development and application of the human intestinal tract chip, a phylogenetic microarray: Analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults
